ProfileGDS5678 / 1450453_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 36% 33% 30% 42% 35% 37% 46% 37% 37% 40% 37% 36% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8432435
GSM967853U87-EV human glioblastoma xenograft - Control 22.8245836
GSM967854U87-EV human glioblastoma xenograft - Control 32.7489733
GSM967855U87-EV human glioblastoma xenograft - Control 42.6415430
GSM967856U87-EV human glioblastoma xenograft - Control 52.915242
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8852635
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9120537
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0682546
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8166537
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8193637
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.924240
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8041937
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8131236
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8159236